Product Information
ALYACEN 7-7-7-28 TABLET is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.2161 per EA under NDC 68462055629. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jan 19, 2012. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462055629
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA091636FDA Approved
1/19/2012
TE Code
AB
On Market Since
1/19/2012
Price Statistics
The NADAC for ALYACEN 7-7-7-28 TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 66.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2161 per EA |
|---|---|
| All-time high | $0.6865 (Apr 13, 2016) |
| All-time low | $0.1916 (Nov 20, 2024) |
| 52-week high | $0.2985 |
| 52-week low | $0.2161 |
| Median price | $0.4516 |
| Average price | $0.4461 |
| Largest weekly change | -36.8% (May 17, 2023) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 6 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 6% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norethindrone and ethinyl estradiol market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ALYACEN 7-7-7-28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ALYACEN 7-7-7-28 TABLET, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.2161 per EA (NDC 68462055629), effective Sep 30, 2026.
How has the price of ALYACEN 7-7-7-28 TABLET changed over time?
Over the history we have for it, the NADAC for ALYACEN 7-7-7-28 TABLET has declined 66.3%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ALYACEN 7-7-7-28 TABLET?
Since Nov 28, 2013, the NADAC for ALYACEN 7-7-7-28 TABLET has ranged from a low of $0.1916 (Nov 20, 2024) to a high of $0.6865 (Apr 13, 2016), with a median of $0.4516 per EA.
Are there cheaper alternatives to ALYACEN 7-7-7-28 TABLET?
Yes. 6 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ALYACEN 1-35 28 TABLET, is $0.2026 per EA — about 6% below ALYACEN 7-7-7-28 TABLET.
Who manufactures ALYACEN 7-7-7-28 TABLET?
ALYACEN 7-7-7-28 TABLET (NDC 68462055629) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.